Andere Sprachen Edgewise Therapeutics, Inc.

Aktien

A2QRZ8

US28036F1057

EWTX

Realtime-Estimate Cboe BZX Andere Börsenplätze 20:22:21 29.04.2024			% 5 Tage	% 1. Jan.
17,09 ^USD	+5,69 %		+15,22 %	+58,82 %

23.04.	EDGEWISE THERAPEUTICS, INC. : RBC Capital Markets bekräftigt seine Kaufempfehlung	ZM
15.04.	Edgewise Therapeutics, Inc. gibt positive Zwei-Jahres-Topline-Ergebnisse der offenen Arch-Studie mit Sevasemten (EDG-5506) bei Erwachsenen mit Becker-Muskeldystrophie (Becker) bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Edgewise Receives European Medicines Agency Orphan Drug Designations for Sevasemten for the Treatment of Becker and Duchenne Muscular Dystrophies	24.04.
Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU	23.04.
Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies	23.04.
Edgewise Therapeutics : EDG-5506 ARCH 2 YR Topline Results	19.04.
Sector Update: Health Care Stocks Mixed Premarket Tuesday	16.04.
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten in Adults with Becker Muscular Dystrophy	16.04.
Edgewise Therapeutics : EDG-5506 ARCH 2 YR Topline Results April 2024	16.04.
Edgewise Therapeutics Reports 'Positive' Two-Year Results From Becker Muscular Dystrophy Trial	15.04.
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)	15.04.
Edgewise Therapeutics, Inc. Announces Positive Two-Year Topline Results from the Arch Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy	15.04.
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session	28.03.
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session	28.03.
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024	27.03.
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024	05.03.
Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference	28.02.
Edgewise Therapeutics Full Year 2023 Net Loss Widens	22.02.
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	22.02.
Edgewise Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22.02.
Edgewise Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22.02.
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy	14.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Edgewise Therapeutics, Inc.

Aktien

A2QRZ8

US28036F1057

EWTX

Andere Sprachen

Filter